BIOC - Biocept, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.4219
-0.0232 (-5.21%)
As of 11:33AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.4451
Open0.4290
Bid0.4233 x 900
Ask0.4248 x 1100
Day's Range0.4100 - 0.4300
52 Week Range0.2100 - 1.2900
Volume6,936,747
Avg. Volume21,614,809
Market Cap55.312M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.7360
Earnings DateAug 10, 2020 - Aug 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
    PR Newswire

    Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air" hosted by Maxim Group and M-Vest on Wednesday, May 27 beginning at 12:00 p.m. Eastern time (9:00 a.m. Pacific time).

  • Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories
    PR Newswire

    Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of a Target Selector™ molecular assay research-use-only (RUO) kit for the detection of BRAF mutations. Biocept's molecular assay kits offer superior sensitivity compared with next generation sequencing (NGS) panels for the detection of biomarkers of key oncogene mutations from a blood sample.

  • Biocept Reports First Quarter 2020 Financial Results
    PR Newswire

    Biocept Reports First Quarter 2020 Financial Results

    Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, reports financial results for the three months ended March 31, 2020 and provides an update on its business progress.

  • Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020
    PR Newswire

    Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three months ended March 31, 2020 after the market closes on Wednesday, May 13, 2020. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

  • Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe
    PR Newswire

    Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the award of CE (Conformité Européene)-IVD Mark for its Target Selector™ molecular assay EGFR Kit. The CE Mark confirms that the Company's Target Selector™ kit products meet the requirements of the European In-Vitro Diagnostic Devices Directive (98/79/EC) and allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies.

  • Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector™ Technology Validated for Use in Both Tissue and Blood Samples
    PR Newswire

    Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector™ Technology Validated for Use in Both Tissue and Blood Samples

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of research-use-only (RUO) kits that can allow molecular laboratories around the world to utilize Biocept's Target Selector™ molecular assay kits to detect key oncogene mutations through the analysis of both Formalin-Fixed Paraffin-Embedded (FFPE) tissue gained from surgical biopsies as well as circulating tumor DNA (ctDNA) gained from blood-based liquid biopsies.

  • Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market
    PR Newswire

    Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market

    Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today announced that on April 14, 2020 it entered into a securities purchase agreement with several institutional investors for the issuance and sale of 22,300,000 shares of its common stock at a price of $0.46 per share, for aggregate gross proceeds of approximately $10.3 million, in a registered direct offering.

  • Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics
    Benzinga

    Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics

    As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.The following companies provided updates Monday on their coronavirus programs.Biocept To Accept COVID-19 Testing Requests San Diego, California-based Biocept Inc (NASDAQ: BIOC), a provider of liquid biopsy tests, said in a Thursday press release that it intends to begin accepting physician-ordered COVID-19 molecular diagnostic testing requests for processing beginning April 15. Biocept said it has partnered with a national clinician network to accept patient samples and may obtain additional agreements as test capacity is increased. The company's lab will use the FDA-approvedThermo Fisher Scientific Inc. (NYSE: TMO) Scientific TaqPath and kit for SARS-CoV2, which received Emergency Use Authorization from the FDA. "I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer," Biocept CEO Mike Nall said in a statement. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.See also: The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates BioCryst Opens Enrollment In Brazilian Trial Of Potential SARS-CoV-2 Treatment BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) said it has opened enrollment into a randomized, double-blind, placebo-controlled clinical study to assess the efficacy and antiviral effects of its galidesivir in patients with COVID-19.The trial will be funded by the National Institute of Allergy and Infectious Diseases, according to the company. Galidesivir is an investigational broad-spectrum antiviral drug that was found to be safe and well-tolerated in an Phase 1 trial conduced in healthy subjects, BioCryst said. It also showed broad-spectrum activity in labs against more than 20 RNA viruses belonging to nine families, including the coronaviruses that cause MERS and SARS.The company said the planned trial will be conducted in Brazil under a U.S. IND, and the protocol has been approved by the Brazilian regulatory agencies."We have begun to see COVID-19 cases in Brazil, and we have a good opportunity to enroll and treat patients earlier in their disease course to determine if galidesivir can benefit patients with COVID-19," said Dr. Esper Kallas, principal investigator of the study.Athersys Gets FDA Nod For Pivotal Phase 2/3 Study Of MultiStem Therapy For COVID-19 Induced ARDS Athersys Inc (NASDAQ: ATHX) said the FDA has authorized the company to initiate a Phase 2/3 pivotal study to assess the safety and efficacy of MultiStem therapy in subjects with moderate-to-severe acute respiratory distress syndrome, or ARDS, induced by the COVID-19 disease.Since the program falls under the company's current IND application for its completed MUST-ARDS study, it is not required to file a new IND.Athersys said it plans to open the first clinical sites for recruitment of the MACOVIA study this quarter. Can-Fite To Begin Enrollment, Dosing In COVID-19 Trial Immediately Can-Fite BioPharma Ltd. (NYSE: CANF) said it has received approval from the Institutional Review Board at Israel's Rabin Medical Center to initiate a pilot clinical study of its drug candidate Piclidenoson for the treatment of moderate-to-severe symptoms in coronavirus infected patients.The company announced in late March that it has submitted Piclidenoson to the institute for a COVID-19 compassionate use program.Patient enrollment and dosing will begin immediately, the company said."Piclidenoson's anti-viral, anti-inflammatory, and anti-rheumatic properties combined with its excellent safety profile make it a strong candidate for the potential treatment of coronavirus," Dr. Pnina Fishman, CEO of Can-Fite, said in a statement. Price Action * Biocept shares were jumping 63.3% to 58 cents at the time of publication Monday. * BioCryst shares were gaining 21.27% to trade at $2.51. * Athersys was moving up 8.59% to $3.16. * Can-Fite shares were surging 44.83% to $2.10. Related Link: Morgan Stanley Downgrades Lilly On Valuation, Says Growth, Pipeline Potential Balanced By Stock Premium See more from Benzinga * The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation * The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests * The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Biocept to Begin COVID-19 Testing
    PR Newswire

    Biocept to Begin COVID-19 Testing

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has verified a COVID-19 molecular diagnostic test, and plans to begin accepting physician-ordered testing requests for processing beginning on April 15, 2020.

  • Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform
    PR Newswire

    Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been granted Brazil Patent No. BR112013028296-7, titled, METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for the Switch-Blocker technology that is core to Biocept's Target Selector™ assays for ctDNA analysis using real-time PCR, Sanger sequencing and next-generation sequencing (NGS).

  • Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform
    PR Newswire

    Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been granted Australia Patent number: 2017268486, titled, METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for Biocept's Primer-Switch technology that is useful for ctDNA analysis using real-time PCR and associated analysis methods, including next-generation sequencing (NGS).

  • For Penny Investors, Biocept Stock Makes a Good Speculative Play
    SmarterAnalyst

    For Penny Investors, Biocept Stock Makes a Good Speculative Play

    Is there room left right now to talk about healthcare companies not connected in any way to a COVID-19 test, vaccine or treatment? Let’s try.Over the past 3 years, Biocept (BIOC) stock has been punished to the tune of a mighty 99.50% decline. Unsurprisingly, the stock is extremely cheap, with each share costing a miniscule $0.27 – enough to put off most investors. But one analyst believes the oncology diagnostics company is heading in the right direction.Maxim’s Jason McCarthy reiterated his Buy rating along with a $1.00 price target. The figure implies potential upside of a massive 257%. (To watch McCarthy’s track record, click here)Along with the vote of confidence, McCarthy has lowered 2020 sales estimates to $8.3 million from $9.4 million on account of the ongoing COVID-19 disruption. As a side note, Biocept has been approached to develop a COVID-19 test, but has declined so far and remains focused on oncology testing.So, what does McCarthy see in a company whose share price has declined so acutely? For starters, the analyst notes Biocept’s growth. Last week, the company released its 4Q19 earnings report with sales of $1.8 million in the quarter indicating year-over-year growth of 108% and an increase of 17% from the prior quarter. “Biocept is feeling the positive effects of management's efforts over the past year to streamline the company's testing platforms and layer in new tests,” noted McCarthy.Additionally, McCarthy argues that management’s efforts to strengthen the company’s strong balance sheet is a “key factor” in his positive assessment and should help it focus on growing the business. Biocept exited 2019 with $9.3 million in cash but raised a further $17 million from two equity financings in March and warrant exercises.Sealing the deal for the Maxim analyst, is the company’s differentiated status in the testing space.McCarthy said, “The inclusion of testing circulating tumor cells (CTCs) along side circulating tumor DNA (ctDNA) is differentiating and should continue to drive adoption, build awareness and keep Biocept above the noise of what can be viewed as a 'crowded' cancer testing space.”To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * Defense Giant Leidos (LDOS) Joins Coronavirus Efforts, Says Analyst * Can Apple Make Its Mark in an Increasingly Competitive Streaming Space? Analyst Weighs In * Amazon (AMZN) Receives Bullish Praise From a Wall Street Pro * Disney’s Streaming Service Could Reach Nearly 70 Million Subscribers by the End of June: Analyst

  • US$1.00: That's What Analysts Think Biocept, Inc. (NASDAQ:BIOC) Is Worth After Its Latest Results
    Simply Wall St.

    US$1.00: That's What Analysts Think Biocept, Inc. (NASDAQ:BIOC) Is Worth After Its Latest Results

    It's been a good week for Biocept, Inc. (NASDAQ:BIOC) shareholders, because the company has just released its latest...

  • Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association
    PR Newswire

    Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into an agreement with a second California-based independent physician association (IPA) to provide its Target Selector™ liquid biopsy assay services to physicians and patients in their network. Biocept's Target Selector™ offering includes the choice of individual biomarker tests or a larger liquid biopsy panel, enabling physicians to select the best approach for each patient.

  • Biocept Reports 2019 Fourth Quarter and Full Year Financial Results
    PR Newswire

    Biocept Reports 2019 Fourth Quarter and Full Year Financial Results

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and 12 months ended December 31, 2019, and provides an update on its business progress.

  • ACCESSWIRE

    Biocept, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 25, 2020 / Biocept, Inc. (NASDAQ:BIOC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 25, 2020 at 4:30 PM Eastern ...

  • ACCESSWIRE

    Biocept, Inc. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network

    LOS ANGELES, CA / ACCESSWIRE / March 18, 2020 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Mike Nall, CEO of Biocept, Inc. (NASDAQ:BIOC), a leading ...

  • Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020
    PR Newswire

    Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020

    Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and 12 months ended December 31, 2019 after the market closes on Wednesday, March 25, 2020. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

  • Biotech Maven Hal Mintz Snaps Up These 3 Small Biotech Stocks
    TipRanks

    Biotech Maven Hal Mintz Snaps Up These 3 Small Biotech Stocks

    It has been three weeks since the coronavirus-driven volatility hit the global economy, and the market continues to rapidly move into both the green and the red. Since its February 19 peak, the S&P 500 has ultimately shed 15% of its value, with it swinging violently in either direction on a seemingly daily basis. As for the other major U.S. indexes, they seem to be following this pattern to a T.Given the uncertainty related to how long the aftermath of the virus’ outbreak will weigh on the market, investors are turning to the pros for guidance, namely healthcare investing guru Hal Mintz. The New York investment banker, who previously managed BAM Capital, has earned a Street reputation as being a trusted source of stock picking inspiration. Currently leading the Sabby Capital hedge fund, which primarily focuses on small-cap healthcare names, Mintz has grown the equity portfolio to reach $361 million, according to the latest 13F filling. As a result, when Mintz makes a move, Wall Street watches.Bearing this in mind, we took a closer look at three small-cap biotech stocks Sabby Capital added to the portfolio recently. After running the tickers through TipRanks’ Stock Screener tool, we found out that analysts see plenty of upside in store for each of these Buy-rated names. Let’s dive in.Zosano Pharma (ZSAN)Using its patented intracutaneous microneedle patch technology, Zosano Pharma wants to provide a safe, simple and fast acting method for drug delivery. While shares have taken a nasty tumble since the start of the year, some believe that a turnaround is on the horizon.Hal Mintz falls into this category. On February 12, Sabby Capital snapped up 3,576,491 shares at $0.65 cents apiece. The total purchase value comes in at more than $2.3 million, with the fund now a 9.99% owner of the company.Based on its Adhesive Dermally Applied Microarray (ADAM) technology, Maxim analyst Anthony Vendetti remains confident in the company’s long-term growth prospects. Specifically pointing to its Qtrypta therapy for migraines and cluster headaches, the analyst noted that there is a significant market opportunity. Among current patients suffering from migraines, 74% receive insufficient treatment, according to a MAST (Migraine in America Symptoms and Treatment) study from 2017. “In our opinion, Qtrypa has the ability to provide a fast, non-oral treatment for migraines, which according to the Migraine Research Foundation, is the third most prevalent disorder in the world,” he stated.The drug’s NDA was accepted by the FDA on March 4, and Vendetti sees gains in store as he believes clinical data supports its approval in October. In the ZOTRIP Phase 2/3 clinical study, the drug was able to provide pain relief in 81% of patients two hours after treatment. Additionally, he reminds investors to consider the implications of the therapy beyond migraines. “Furthermore, we believe the company's ADAM technology can be used as a drug delivery system for future immunotherapy, proteins, and biologics,” he explained.The analyst concluded, "The acceptance of the NDA for Qtrypta by the FDA represents another positive step towards bringing an innovative therapy for migraine sufferers to market, and we believe that the capital raises get ZSAN closer to the PDUFA goal date of October 20, 2020, a potentially transformative date for the company. We are bullish on the opportunity for its Adhesive Dermally Applied Microarray (ADAM) technology."As a result, Vendetti rates Zosano shares a "buy" alongside a $2.00 price target which implies nearly 260% upside from current levels. (To watch Vendetti’s track record, click here)Biocept Inc. (BIOC)Biocept is developing cutting-edge diagnostic solutions that can possibly provide critical information to both cancer patients and doctors using a simple blood test called liquid biopsy. Given the technology’s potential, some members of the Street see big things in store.This is the case for Mintz as his fund added a BIOC holding to the portfolio on March 2. Acquiring a 9.71% stake in the company, Sabby Capital spent $3.6 million to buy 9 million shares.Like Mintz, Maxim Group’s Jason McCarthy has high hopes for the biotech. He doesn’t dispute the fact that in liquid biopsy, the actual circulating tumor DNA (ctDNA) only represents a small percentage of circulating DNA and the rest gets released as a normal part of the cell’s life cycle in the form of cfDNA. That being said, he points out, “Biocept’s Switch-Blocker technology is designed to suppress amplification of wild-type targets, without suppressing mutant sequences containing even one single nucleotide variant (SNV). On top of this, the technology allows for real-time PCR.It doesn’t hurt that the “Clinical validation of qPCR Target Selector assays using highly specific switch-blockers for rare mutation detection” study supports the use of liquid biopsy and switch blocker technology. In the study, which looked at the EGFR, BRAF and KRAS gene mutations, a high concordance between Target Selector liquid biopsy and traditional biopsy was discovered.“Demonstrating concordance to tissue is an essential step in establishing a liquid biopsy. Tissue is the gold standard, though isn't always practical and can have issues relating to tumor heterogeneity. The new data helps further display the performance of Target Selector, which should help drive continued adoption in 2020,” McCarthy commented.It should also be noted that these mutations are seen in several types of cancers, and that two approved therapies, Tagrisso and Mekinist, targeting these mutations generated $3 billion and $1.3 billion, respectively, in 2019.To this end, McCarthy stayed with the bulls, reiterating his Buy rating and $1 price target. Should the target be met, a 186% twelve-month gain could be in the cards. (To watch McCarthy’s track record, click here)Heat Biologics (HTBX)With its proprietary T-cell Activation Platform (TCAP), Heat Biologics has been able to create therapies that enable a patient’s own immune system to defend itself against cancer cells. Its two platforms, ImPACT and ComPACT, were designed based on the heat shock protein, gp96. Among the biotech’s fans is the Sabby Capital manager. His fund added a new position comprised of 4.3 million shares at $0.35 per share. The total purchase value comes in at more than $1.5 million, with the fund now a 7.49% owner of the company. More recently, HTBX has made a splash after it announced that through its subsidiary, Zolovax, it is launching a coronavirus vaccine program. Using gp96, the biotech will design a vaccine that takes advantage of the protein’s immune activating capabilities. According to Jason McCarthy, who also covers this stock, the fact that gp96 is used in both oncology and infectious diseases makes it especially promising in the battle against coronavirus.In addition, McCarthy believes that the technology’s efficacy in other infectious diseases bodes well for the company. “Previously, the gp96 platform has been evaluated in numerous NIH (National Institutes of Health) and DOD (U.S. Department of Defense)-funded preclinical trials, against HIV/SIV, malaria, Zika and other infectious diseases. The results demonstrated potent immune response and induction of mucosal immunity in animal models,” the analyst noted.Even though HTBX has been weighed down thanks to exchange agreements around warrants, McCarthy points out that since February 28, shares are up 82%.Based on all of the above, McCarthy left both his Buy rating and $1 price target unchanged. This conveys his confidence in HTBX’s ability to soar 67% in the next twelve months.To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector™ qPCR Assay to Identify Cancer-Associated Mutations
    PR Newswire

    Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector™ qPCR Assay to Identify Cancer-Associated Mutations

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of clinical data in the peer-reviewed Journal of Clinical Pathology that further validates the Company's Target Selector™ qPCR Assay using "Switch Blocker" technology to identify cancer-related mutations in liquid biopsy samples. The article can be found at https://jcp.bmj.com/content/early/2020/03/04/jclinpath-2019-206381.

  • Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market
    PR Newswire

    Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market

    Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today announced that on March 4, 2020 it entered into a securities purchase agreement with several institutional investors for the issuance and sale of 16,000,000 shares of its common stock at a price of $0.41 per share, for aggregate gross proceeds of approximately $6.6 million, in a registered direct offering priced at-the-market under Nasdaq rules. The Company currently expects that the proceeds from this registered direct offering, along with the approximate $9.2 million in gross proceeds from the Company's registered direct offering announced on March 2, 2020 and its current cash and cash equivalents, will be sufficient to fund its current operations through at least December 31, 2020.

  • MarketWatch

    Biocept's stock plummets on heavy volume after share offering prices at deep discount

    Shares of Biocept Inc. plummeted 42% on very heavy volume in morning trading Monday, after the provider of liquid cancer tests announced the pricing of stock offering at a deep discount. The company said it agreed on the issuance and sale of 23 million shares of common stock to several institutional investors, which would increase the shares outstanding by about 54%, according to FactSet data. The offering was priced at 40 cents a share, or 49% below Friday's closing price of 78 cents. The pricing was announced after the stock rocketed 169% on Friday. Maxim Group is the sole placement agent for the offering. Trading volume ballooned to 45.4 million shares, enough to make the stock the most actively traded on major U.S. exchanges, and well above the full-day average of about 6.1 million shares. The stock has now lost 57% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has gained 0.4% and the S&P 500 has advanced 6.4%.

  • Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market
    PR Newswire

    Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market

    Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today announced that it has entered into a securities purchase agreement with several institutional investors for the issuance and sale of 23,000,000 shares of its common stock at a price of $0.40 per share, for aggregate gross proceeds of approximately $9.2 million, in a registered direct offering priced at-the-market under Nasdaq rules.

  • Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations
    PR Newswire

    Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the promotion of Cory J. Dunn, M.S., M. Ed. to Senior Vice President of Commercial Operations. Ms. Dunn succeeds Edwin Hendrick, who resigned to pursue other endeavors.

  • Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association
    PR Newswire

    Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into an agreement with a California-based independent physician association (IPA) to provide its liquid biopsy testing services to physicians and patients in their network. Biocept's Target Selector™ offering includes the choice of individual biomarker tests or a larger liquid biopsy panel, enabling physicians to select the best approach for each patient.